A scientist at a stereo microscope in a laboratory, working in protective gear.

Pipeline

Best-in-class vaccines, built on one platform

Protein cages are synthetic virus-like particles that display biological material on their surface, or carry molecules such as nucleic acids or proteins into the cell. Our cages are programmable, which gives them significant potential as both drug delivery systems and vaccines.

Product	Stage of development	Rationale for market entry	Phase start
Combo RSV/hMPV Vaccine	Design of VLP	There are currently no vaccines for hMPV. RSV vaccines are yet to be trialled in large populations, and options for patients are limited.	2026
Combo Covid/Flu Vaccine	Challenge animal experiments	Elderly patients are recommended to have both Covid and flu boosters. No combination option is available.	2026
Lyme Disease Vaccine	Design of VLP	There is currently no vaccine for Lyme disease. A growing problem in the US and Western Europe. The disease carries long-term complications.	2027

Combo RSV/hMPV Vaccine

Stage of development: Design of VLP
Rationale for market entry: There are currently no vaccines for hMPV.
RSV vaccines are yet to be trialled in large populations, and options for patients are limited.
Phase start: 2026
Partner

Combo Covid/Flu Vaccine

Stage of development: Challenge animal experiments
Rationale for market entry: Elderly patients are recommended to have both Covid and flu boosters.
No combination option is available.
Phase start: 2026
Partner

Lyme Disease Vaccine

Stage of development: Design of VLP
Rationale for market entry: There is currently no vaccine for Lyme disease.
A growing problem in the US and Western Europe.
The disease carries long-term complications.
Phase start: 2027
Partner